October 3, 2011
Toyobo announced on September 20 that its subsidiary Toyobo Biologics Inc. (TBI) concluded a partnership with Catalent Pharma Solutions, Inc. on August 15. The agreement will allow TBI to expand its contract development and manufacturing of antibody drugs using Catalent’s...read more